Key facts
- It has raised $80.5M across 4 recorded rounds; the latest was Seed Round ($3.3M) in Jan 2025.
- Notable investors include Next Coast Ventures, Kineticos Life Sciences Management.
- Inceptor Bio has filed 6 Form Ds with the SEC since 2020, most recently Jan 2025 ($3.3M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Inceptor Bio
Funding rounds
4 roundsAbout Inceptor Bio
Operator of a biotechnology platform intended for advancing research and developing therapies to cure cancer. The company's platform identifies, incubates, and accelerates novel cell and genetic therapy technologies that maintain stemness and effector function within the tumor microenvironment to enhance immune cell performance and resistance to exhaustion, providing patients with improved cancer treatment.
- Sector
- Healthcare
- HQ
- Morrisville, NC, United States
- Founded
- 2020
- Employees
- 23
- Website
- inceptor.bio/
- Ownership
- Privately Held (backing)
Inceptor Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inceptor Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inceptor Bio in its N-PORT filings yet. We sweep new filings monthly.